{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:10Z","timestamp":1786979890687,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00259-025-07634-z","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:44:10Z","timestamp":1762508650000},"page":"2282-2294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of [177Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0426-8536","authenticated-orcid":false,"given":"Ren\u00e9","family":"Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Soza-Ried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasko","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korbinian","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Fliegert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Ritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Zhernosekov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Estay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Nicolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"7634_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77:38\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.005.","journal-title":"Eur Urol"},{"key":"7634_CR2","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180\u201392. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02799.x.","journal-title":"Int J Clin Pract"},{"key":"7634_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3747\/co.v17i2.482","volume":"17","author":"SN Chin","year":"2010","unstructured":"Chin SN, Wang L, Moore M, Sridhar SS. A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret hospital. Curr Oncol. 2010;17:24\u20139. https:\/\/doi.org\/10.3747\/co.v17i2.482.","journal-title":"Curr Oncol"},{"key":"7634_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2340\/1651-226X.2025.42173","volume":"64","author":"A Rannikko","year":"2025","unstructured":"Rannikko A, Holsa O, Agesen T, Ekman M, Mattila R. Real-world treatment patterns and survival outcomes in men with metastatic castration-resistant prostate cancer in Finland: a national, population-based cohort study. Acta Oncol. 2025;64:173\u20138. https:\/\/doi.org\/10.2340\/1651-226X.2025.42173.","journal-title":"Acta Oncol"},{"key":"7634_CR5","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/JU.0000000000001570","volume":"205","author":"N Shore","year":"2021","unstructured":"Shore N, Oliver L, Shui I, Gayle A, Wong OY, Kim J, et al. Systematic literature review of the epidemiology of advanced prostate cancer and associated homologous recombination repair gene alterations. J Urol. 2021;205:977\u201386. https:\/\/doi.org\/10.1097\/JU.0000000000001570.","journal-title":"J Urol"},{"key":"7634_CR6","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/pros.23795","volume":"79","author":"M Oh","year":"2019","unstructured":"Oh M, Alkhushaym N, Fallatah S, Althagafi A, Aljadeed R, Alsowaida Y, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis. Prostate. 2019;79:880\u201395. https:\/\/doi.org\/10.1002\/pros.23795.","journal-title":"Prostate"},{"key":"7634_CR7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"7634_CR8","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"7634_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231157632","volume":"15","author":"A Jang","year":"2023","unstructured":"Jang A, Kendi AT, Sartor O. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol. 2023;15:17588359231157632. https:\/\/doi.org\/10.1177\/17588359231157632.","journal-title":"Ther Adv Med Oncol"},{"key":"7634_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020256","author":"KE de Roode","year":"2024","unstructured":"de Roode KE, Joosten L, Behe M. Towards the magic radioactive bullet: improving targeted radionuclide therapy by reducing the renal retention of radioligands. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17020256.","journal-title":"Pharmaceuticals (Basel)"},{"key":"7634_CR11","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1021\/acs.molpharmaceut.4c00095","volume":"21","author":"MD Pun","year":"2024","unstructured":"Pun MD, Gallazzi F, Ho KV, Watkinson L, Carmack TL, Iweha E, et al. Albumin-binding lutetium-177-labeled LLP2A derivatives as theranostics for melanoma. Mol Pharm. 2024;21:2960\u20139. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00095.","journal-title":"Mol Pharm"},{"key":"7634_CR12","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","volume":"15","author":"CA Umbricht","year":"2018","unstructured":"Umbricht CA, Benesova M, Schibli R, Muller C. Preclinical development of novel PSMA-Targeting radioligands: modulation of Albumin-Binding properties to improve prostate cancer therapy. Mol Pharm. 2018;15:2297\u2013306. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00152.","journal-title":"Mol Pharm"},{"issue":"3","key":"7634_CR13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00259-020-05022-3","volume":"48","author":"V Kramer","year":"2021","unstructured":"Kramer V, Fernandez R, Lehnert W, Jimenez-Franco LD, Soza-Ried C, Eppard E, et al. Biodistribution and dosimetry of a single dose of albumin-binding ligand [(177)Lu]Lu-PSMA-ALB-56 in patients with mCRPC. Eur J Nucl Med Mol Imaging. 2021;48(3):893\u2013903. https:\/\/doi.org\/10.1007\/s00259-020-05022-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7634_CR14","doi-asserted-by":"publisher","unstructured":"Sallam M, Nguyen NT, Sainsbury F, Kimizuka N, Muyldermans S, Benesova-Schafer M. PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?. Theranostics. 2024;14:3043\u201379. https:\/\/doi.org\/10.7150\/thno.92612","DOI":"10.7150\/thno.92612"},{"key":"7634_CR15","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.7150\/thno.96675","volume":"14","author":"Y Song","year":"2024","unstructured":"Song Y, Zou J, Castellanos EA, Matsuura N, Ronald JA, Shuhendler A, et al. Theranostics - a sure cure for cancer after 100 years? Theranostics. 2024;14:2464\u201388. https:\/\/doi.org\/10.7150\/thno.96675.","journal-title":"Theranostics"},{"key":"7634_CR16","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1021\/acs.molpharmaceut.1c00994","volume":"19","author":"F Borgna","year":"2022","unstructured":"Borgna F, Deberle LM, Busslinger SD, Tschan VJ, Walde LM, Becker AE, et al. Preclinical investigations to explore the difference between the diastereomers [(177)Lu]Lu-SibuDAB and [(177)Lu]Lu-RibuDAB toward prostate cancer therapy. Mol Pharm. 2022;19:2105\u201314. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00994.","journal-title":"Mol Pharm"},{"key":"7634_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07102-8","author":"P Ritt","year":"2025","unstructured":"Ritt P, Fernandez R, Soza-Ried C, Nicolai H, Amaral H, Krieger K, et al. Biodistribution and dosimetry of [(177)Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07102-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7634_CR18","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.2967\/jnumed.124.267452","volume":"65","author":"Z Ells","year":"2024","unstructured":"Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. Dosimetry of [(177)Lu]Lu-PSMA-targeted radiopharmaceutical therapies in patients with prostate cancer: a comparative systematic review and metaanalysis. J Nucl Med. 2024;65:1264\u201371. https:\/\/doi.org\/10.2967\/jnumed.124.267452.","journal-title":"J Nucl Med"},{"key":"7634_CR19","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.7150\/thno.40482","volume":"10","author":"LM Deberle","year":"2020","unstructured":"Deberle LM, Benesova M, Umbricht CA, Borgna F, Buchler M, Zhernosekov K, et al. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics. 2020;10:1678\u201393. https:\/\/doi.org\/10.7150\/thno.40482.","journal-title":"Theranostics"},{"key":"7634_CR20","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2967\/jnumed.121.263072","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, et al. Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic Castration-Resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;63:1651\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.263072.","journal-title":"J Nucl Med"},{"key":"7634_CR21","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(10)61389-X.","journal-title":"Lancet"},{"issue":"15","key":"7634_CR22","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312. https:\/\/doi.org\/10.1056\/NEJMoa040720.","journal-title":"N Engl J Med"},{"key":"7634_CR23","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1715546.","journal-title":"N Engl J Med"},{"key":"7634_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1405095.","journal-title":"N Engl J Med"},{"key":"7634_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1209096.","journal-title":"N Engl J Med"},{"key":"7634_CR26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686\u2013700. https:\/\/doi.org\/10.1016\/S1470-2045(19)30082-8.","journal-title":"Lancet Oncol"},{"key":"7634_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395\u2013405. https:\/\/doi.org\/10.1200\/JCO.19.01638.","journal-title":"J Clin Oncol"},{"key":"7634_CR28","unstructured":"(2021) RCT. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.; 2021."},{"key":"7634_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1080\/21681805.2021.1871644","volume":"55","author":"T Jurys","year":"2021","unstructured":"Jurys T, Durmala J. Quality of life assessment using EORTC QLQ questionnaires in the prostate cancer population treated with radical prostatectomy: a systematic review. Scand J Urol. 2021;55:90\u20137. https:\/\/doi.org\/10.1080\/21681805.2021.1871644.","journal-title":"Scand J Urol"},{"key":"7634_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14014","volume":"53","author":"L Giovanella","year":"2023","unstructured":"Giovanella L, Garo ML, Cuzzocrea M, Paone G, Herrmann K. Prognostic role of early prostate specific antigen changes after [(177) Lu]Lu-PSMA radioligand therapy of metastasized prostate cancer: a meta-analysis. Eur J Clin Invest. 2023;53:e14014. https:\/\/doi.org\/10.1111\/eci.14014.","journal-title":"Eur J Clin Invest"},{"key":"7634_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00891-1","volume":"12","author":"F Kind","year":"2022","unstructured":"Kind F, Michalski K, Yousefzadeh-Nowshahr E, Meyer PT, Mix M, Ruf J. Bone marrow impairment during early [(177)Lu]PSMA-617 radioligand therapy: haematotoxicity or tumour progression? EJNMMI Res. 2022;12:20. https:\/\/doi.org\/10.1186\/s13550-022-00891-1.","journal-title":"EJNMMI Res"},{"key":"7634_CR32","doi-asserted-by":"publisher","unstructured":"Busslinger SD, Tschan VJ, Richard OK, Talip Z, Schibli R, Muller C. [(225)Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: preclinical evaluation and comparison with [(225)Ac]Ac-PSMA-617. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14225651.","DOI":"10.3390\/cancers14225651"},{"key":"7634_CR33","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2967\/jnumed.123.265524","volume":"64","author":"VJ Tschan","year":"2023","unstructured":"Tschan VJ, Busslinger SD, Bernhardt P, Grundler PV, Zeevaart JR, Koster U, et al. Albumin-binding and conventional PSMA ligands in combination with (161)Tb: biodistribution, dosimetry, and preclinical therapy. J Nucl Med. 2023;64:1625\u201331. https:\/\/doi.org\/10.2967\/jnumed.123.265524.","journal-title":"J Nucl Med"},{"key":"7634_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.2967\/jnumed.122.264402","volume":"64","author":"A Karimzadeh","year":"2023","unstructured":"Karimzadeh A, Heck M, Tauber R, Knorr K, Haller B, D\u2019Alessandria C, et al. (177)Lu-PSMA-I&T for treatment of metastatic Castration-Resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers. J Nucl Med. 2023;64:402\u20139. https:\/\/doi.org\/10.2967\/jnumed.122.264402.","journal-title":"J Nucl Med"},{"key":"7634_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-022-01050-3","volume":"22","author":"R Wrenger","year":"2022","unstructured":"Wrenger R, Juptner M, Marx M, Zhao Y, Zuhayra M, Caliebe A, et al. Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy. BMC Urol. 2022;22:96. https:\/\/doi.org\/10.1186\/s12894-022-01050-3.","journal-title":"BMC Urol"},{"key":"7634_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/MOU.0000000000000486","volume":"28","author":"J Ferdinandus","year":"2018","unstructured":"Ferdinandus J, Violet J, Sandhu S, Hofman MS. Prostate-specific membrane antigen theranostics: therapy with lutetium-177. Curr Opin Urol. 2018;28:197\u2013204. https:\/\/doi.org\/10.1097\/MOU.0000000000000486.","journal-title":"Curr Opin Urol"},{"key":"7634_CR37","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2967\/jnumed.116.178228","volume":"58","author":"J Ferdinandus","year":"2017","unstructured":"Ferdinandus J, Eppard E, Gaertner FC, Kurpig S, Fimmers R, Yordanova A, et al. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. J Nucl Med. 2017;58:312\u20139. https:\/\/doi.org\/10.2967\/jnumed.116.178228.","journal-title":"J Nucl Med"},{"key":"7634_CR38","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","volume":"47","author":"J Ferdinandus","year":"2020","unstructured":"Ferdinandus J, Violet J, Sandhu S, Hicks RJ, Ravi Kumar AS, Iravani A, et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020;47:2322\u20137. https:\/\/doi.org\/10.1007\/s00259-020-04723-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7634_CR39","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.euo.2023.07.018","volume":"7","author":"M Kafka","year":"2024","unstructured":"Kafka M, Horninger A, di Santo G, Virgolini I, Neuwirt H, Unterrainer LM, et al. Real-world outcomes and predictive biomarkers for (177)Lutetium prostate-specific membrane antigen ligand treatment in metastatic castration-resistant prostate cancer: a European association of urology young academic urologists prostate cancer working group multi-institutional observational study. Eur Urol Oncol. 2024;7:421\u20139. https:\/\/doi.org\/10.1016\/j.euo.2023.07.018.","journal-title":"Eur Urol Oncol"},{"key":"7634_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1055\/a-1670-9500","volume":"61","author":"CA Schneider","year":"2022","unstructured":"Schneider CA, Tager P, Hammes J, Fischer T, Drzezga A, Pfister D, et al. Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer. Nuklearmedizin. 2022;61:25\u201332. https:\/\/doi.org\/10.1055\/a-1670-9500.","journal-title":"Nuklearmedizin"},{"key":"7634_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-025-01229-3","volume":"15","author":"S Yadav","year":"2025","unstructured":"Yadav S, Tuchayi AM, Moradpour M, Jiang F, Juarez R, de Kouchkovsky I, et al. Pre- or post-chemotherapy: effect on PSMA uptake. EJNMMI Res. 2025;15:36. https:\/\/doi.org\/10.1186\/s13550-025-01229-3.","journal-title":"EJNMMI Res"},{"key":"7634_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251375","volume":"16","author":"MP Yadav","year":"2021","unstructured":"Yadav MP, Ballal S, Sahoo RK, Tripathi M, Damle NA, Shamim SA, et al. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients. PLoS ONE. 2021;16:e0251375. https:\/\/doi.org\/10.1371\/journal.pone.0251375.","journal-title":"PLoS ONE"},{"key":"7634_CR43","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41416-020-01050-w","volume":"123","author":"K Cooper","year":"2020","unstructured":"Cooper K, Tappenden P, Cantrell A, Ennis K. A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer. Br J Cancer. 2020;123:1686\u201396. https:\/\/doi.org\/10.1038\/s41416-020-01050-w.","journal-title":"Br J Cancer"},{"key":"7634_CR44","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008;26:1148\u201359. https:\/\/doi.org\/10.1200\/JCO.2007.12.4487.","journal-title":"J Clin Oncol"},{"key":"7634_CR45","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1007\/s00259-024-07009-w","volume":"52","author":"A Chirindel","year":"2025","unstructured":"Chirindel A, Nicolas GP, Westerbergh F, McDougall L, Schmid DE, Geistlich S, et al. First-in-human administration of [(161)Tb]Tb-SibuDAB and comparative dosimetry with standard [(177)Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study. Eur J Nucl Med Mol Imaging. 2025;52:1628\u201330. https:\/\/doi.org\/10.1007\/s00259-024-07009-w.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07634-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07634-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07634-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:39:06Z","timestamp":1771479546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07634-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7634"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07634-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments. The study was approved by the regional ethics committee board (CEC SSM Oriente, permit 20210521).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent for participation and publication was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publish"}},{"value":"The authors declare the following competing financial interest(s): Patent applications on PSMA ligands with albumin-binding entities have been filed by ITM Medical Isotopes GmbH, Germany and the Paul Scherrer Institute, Switzerland. KZ and CM are listed as co-inventors. The authors further declare non-financial interest(s): non-carrier-added lutetium-177 was provided by ITM Medical Isotopes GmbH, Germany.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}